Announcements, press, and milestones.

Aulis Capital was delighted to take part in the biotech panel at the HKVCA 25th Anniversary Greater China Private Equity Summit at HKCEC on May 19.

Our Venture Partner Paul Li joined moderator Frank Yang (Blue Ocean Capital) and fellow panelists Kevin Chow (Bayland Capital), Dr. Mia Hu (Boehringer Ingelheim), and Cillian King (EQT Life Sciences) for a candid conversation on the state of Greater China biotech.

A huge thank you to HKVCA for convening such a high-caliber community, and congratulations on 25 remarkable years of building and championing private capital in the region. Here’s to the conversations, collaborations, and companies still to come.

#HKVCA25 #Biotech #PrivateEquity #LifeSciences #HongKong

Yesterday at HKCEC, our Managing Partner Nisa Leung led the discussion at “The Next Frontier in China’s Healthcare Industry” — a thematic panel at the 6th Asia Summit on Global Health (ASGH), hosted by HKTDC.

We are grateful to all the panelists for sharing their perspectives on how China’s healthcare sector is evolving and to HKTDC for the opportunity to take part.

#ASGH2026 #china #healthcare #biotech

Our Venture Partner Franck Le Deu joined The 26th Bio€quity Europe in Prague for the 8th East-West Roundtable: “Sourcing Innovation from Asia — What’s in it for Europe?” alongside a thoughtful group of investors and operators.

Cross-border collaboration and smart partnering were the threads running through the discussion. Thank you to BioCentury for hosting, and to our fellow panelists and the room for an engaged debate.

Looking forward to continuing the conversations sparked in Prague.

#BioEquityEurope #drugdevelopment #venturecapital #China #biotech #newco #Healthcare #Innovation #GlobalBiotech

Our colleague Mingyu Xue, Ph. D. participated as a panelist in the session “China for Global – Real World Case Studies in Going Global” at CHINABIO® 2026.

The discussion moved beyond high‑level themes to examine concrete China–global deal and expansion case studies, covering how partnerships were structured, the capabilities required across discovery, clinical development, and commercialization, and key learnings from cross‑border collaboration. Mingyu contributed practical perspectives drawn from real‑world experience, helping translate headline deals into actionable insights for the broader ecosystem.

We were pleased to see Mingyu represent our team and contribute to this timely and relevant conversation on global growth pathways for Chinese biotechs and biopharmas.

#CHINABIO2026 #ChinaForGlobal #Panelist #Biotech #LifeSciences #GlobalExpansion #IndustryInsights #Aulis

Milestone achieved at EpiBiologics: first patient dosed in the Phase 1 study of EPI‑326, advancing a novel approach to address unmet needs in EGFR‑driven cancers. Congratulations to the entire EpiBiologics team.

#Biotech #Oncology #ClinicalDevelopment #EGFR #DrugDiscovery #PatientCentricInnovation

We are delighted to welcome Dr. Lingshi Tan to Aulis as Venture Partner. Dr. Tan was formerly CEO of Caidya, where he now serves as Executive Chairman. Dr. Tan founded dMed Clinical Company (dMed) in 2016. Following a series of acquisitions, dMed established the global brand name Caidya in 2022, providing a full range of services to clients and patient populations across several therapeutic areas in the Americas, Europe, and Asia-Pacific.

Prior to founding dMed, Dr. Tan served for nearly 20 years in global management roles at Pfizer. After leading a Global Biometrics team, he was appointed Pfizer’s Vice President of Worldwide Development Operations and founded Pfizer (China) Research & Development Co., Ltd. Dr. Tan is a past chairman of the DIA Global Board of Directors.

Proud to share that our Founding Managing Partner Nisa Leung has been featured in Mergermarket APAC’s spotlight on APAC dealmaking leaders. Thank you to ION Analytics for highlighting the diverse paths shaping leadership in M&A, investing, law, and capital markets.

#APAC #VC #VentureCapital #MergersAndAcquisitions #Healthcare #Biotech

We are delighted to welcome Franck Le Deu to Aulis as Venture Partner. Franck will help build the Life Sciences practice in China and Asia and bridging the West and the East and give strategic advice to the fund as well as our portfolio companies.

Aulis Capital is pleased to announce our investment in EpiBiologics’ $107M Series B financing. EpiBiologics is advancing a next-generation protein degradation pipeline and platform that targets extracellular membrane and soluble proteins. The Company’s proprietary EpiTAC platform is a modular bispecific antibody system that enables targeted degradation of disease-driving extracellular proteins in a tissue-specific manner.

With this financing, EpiBiologics will advance their pipeline of novel bispecific antibodies to selectively degrade disease-driving membrane and soluble targets in oncology and immunology. EpiBiologics aims to develop first-in-class and best-in-class targeted therapies across multiple therapeutic areas, including oncology and immunology.

#EpiBiologics #EGFR #Lungcancer #NSCLC #HNSCC